Secondary analysis of the NRG GY017 trial of atezolizumab with chemoradiation for node-positive locally advanced cervical cancer: 13 of 37 (35%) pretreatment IMRT plans had major deviations on central review and needed revision, mostly for contours.
Secondary analysisn = 37
Mayadev et al. Radiation Quality and Workflow in NRG GY017: Anti-PD-L1 (Atezolizumab) as an Immune Primer or Concurrently With Radiation Therapy for Node-Positive Locally Advanced Cervical Cancer